Clinical Trial

PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to assess the pharmacokinetics and pharmacodynamics of gefurulimab in pediatric participants with AChR+ gMG for the duration of the study.
Protocol Amendment History 13 amendments
This ClinicalTrials.gov record has been amended 13 times since 2024-09-19; most recent amendment 2026-03-31.
Status change: Not Yet Recruiting → Recruiting 2024-12-05
Trial Details
NCT Number NCT06607627
Lead Sponsor Alexion Pharmaceuticals, Inc.
Conditions Generalized Myasthenia Gravis, gMG
Enrollment 12 participants
Start Date 2024-11-13
Primary Completion 2026-12-15 (estimated)
Study Completion 2029-01-23 (estimated)
Updated on ClinicalTrials.gov 2026-04-01